Login / Signup

Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide.

Jakob Schöllhammer KnudsenReimar Wernich ThomsenAnton PottegårdFilip Krag KnopHenrik Toft Sørensen
Published in: Diabetes care (2018)
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • peritoneal dialysis
  • clinical trial
  • patient reported outcomes